If you were to walk into most of the world’s hackerspaces, it’s likely that the most frequent big-ticket tool you’ll find after a 3D printer is a laser cutter. A few years ago that would inevitably ...

AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...